Type 2 diabetes specifically attenuates purinergic skin vasodilatation without affecting muscarinic and nicotinic skin vasodilatation and sweating
Type 2 diabetes specifically attenuates purinergic skin vasodilatation without affecting muscarinic and nicotinic skin vasodilatation and sweating
复制标题
DOI：
10.1113/ep086694
复制
发表时间：
2018-02-01
影响因子：
2.7
通讯作者：
Kenny, Glen P.
中科院分区：
文献类型：
--
作者：
Fujii, Naoto;Meade, Robert D.;Kenny, Glen P.
本研究评估2型糖尿病（T2 D）是否减弱毒蕈碱和/或烟碱皮肤血管扩张和出汗以及嘌呤能皮肤血管扩张。对12名健康非糖尿病老年人的皮肤血管传导性和出汗率进行了评价（对照组，60 +/-8岁）和13例老年T2 D患者（62 +/-10岁）在前臂皮内皮肤部位灌注以下药物：（i）乙酰甲胆碱（毒蕈碱受体激动剂，五种剂量：0.0125、0.25、5、100和2000 mM）;（ii）尼古丁（烟碱受体激动剂，五个剂量：1.2、3.6、11、33和100 mm）;或（iii）ATP（嘌呤能受体激动剂，五个剂量：0.03、0.3、3、30和300 mm）。每种激动剂每次给药25 min。在方案结束时，对所有皮肤部位给予50 mm硝普钠，以引起最大皮肤血管舒张。乙酰甲胆碱和尼古丁给药期间的皮肤血管传导性在组间无差异（均P>0.05）。相比之下，与对照受试者相比，T2 D受试者在30 mm ATP（42 +/- 28 vs 63 +/- 26%最大值，P0.05）和300 mm ATP（56 +/- 24 vs 71 +/- 20%最大值，P0.05）给药期间的皮肤血管传导减弱。此外，T2 D患者在给予50 mm硝普钠期间的皮肤血管传导性低于对照受试者（P=0.04）。乙酰甲胆碱和尼古丁诱导的出汗在组间相似（均P>0.05）。因此，T2 D减弱嘌呤能皮肤血管舒张，而不影响毒蕈碱和烟碱皮肤血管和出汗反应。
The present study evaluated whether type 2 diabetes (T2D) attenuates muscarinic and/or nicotinic cutaneous vasodilatation and sweating as well as purinergic cutaneous vasodilatation. Cutaneous vascular conductance and sweat rate were evaluated in 12 healthy non-diabetic older adults (Control, 60 +/- 8years) and 13 older adults with T2D (62 +/- 10years) at three intradermal forearm skin sites perfused with the following: (i) methacholine (muscarinic receptor agonist, five doses: 0.0125, 0.25, 5, 100 and 2000mm); (ii) nicotine (nicotinic receptor agonist, five doses: 1.2, 3.6, 11, 33 and 100mm); or (iii) ATP (purinergic receptor agonist, five doses: 0.03, 0.3, 3, 30 and 300mm). Each agonist was administered for 25min per dose. At the end of the protocol, 50mm sodium nitroprusside was administered to all skin sites to elicit maximal cutaneous vasodilatation. Cutaneous vascular conductance during methacholine and nicotine administration did not differ between groups (all P>0.05). In contrast, cutaneous vascular conductance during administration of 30mm (42 +/- 28 versus 63 +/- 26% maximum, P0.05) and 300mm ATP (56 +/- 24 versus 71 +/- 20% maximum, P0.05) was attenuated in individuals with T2D in comparison to the Control participants. Furthermore, cutaneous vascular conductance during administration of 50mm sodium nitroprusside was lower in individuals with T2D relative to Control subjects (P=0.04). Methacholine- and nicotine-induced sweating was similar between groups (all P>0.05). Thus, T2D attenuates purinergic cutaneous vasodilatation without affecting muscarinic and nicotinic cutaneous vascular and sweating responses.